Recruiting

Observational Study

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT07232043

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MatchMiner-AI Artificial Intelligence Tool

Study Details

Brief summary:

This study aims to develop and evaluate ACTIVATE, an AI-driven tool for clinical trial information and viability assessment using electronic health records (EHRs). The project will leverage retrospective and prospective EHR data to build and validate algorithms that identify potentially eligible participants for clinical trials and facilitate trial matching.

Conditions

Cancer

Study ID

NCT07232043

Start date

Jul 20, 2026

Status verified date

Sep, 2026

Completion date

Jun 30, 2030

Anticipated

Primary completion date

Jun 30, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 3.1 The potentially eligible patient population includes any adult (≥18 years old) with a cancer diagnosis receiving care at DFCI. No direct patient recruitment will occur as part of this protocol; all data will be obtained retrospectively or prospectively from routine clinical documentation and electronic health records. TrialForecast will involve aggregate queries of this dataset for cohort size estimation. The randomized interventional component (TrialMatch) is a health system level email "nudge" to treating oncologists providing a list of clinical trial options for patients who have progressive disease based on their imaging reports as detected using our previously developed, validated, and deployed AI model for that purpose. 23-25 Secondary outcomes in our study will include oncologist satisfaction with information delivered via these pipelines. All DFCI oncologists at any DFCI-owned/operated site (Longwood, Chestnut Hill, and regional campus sites) will be eligible to use our pipeline and may receive notifications about clinical trial options for their patients. In 2024, there were approximately 593 such oncologists who had outpatient appointments with at least one patient. Clinicians will constitute study participants as well, since they will have the opportunity to provide feedback on our pipeline to be analyzed by the study team.
  • 3.2 Our project will focus on adults with cancer treated at DFCI, as above. We will not have any mechanism for identifying, targeting, or excluding pregnant women or prisoners.

Exclusion Criteria:

  • 3.2 Our project will focus on adults with cancer treated at DFCI, as above. We will not have any mechanism for identifying, targeting, or excluding pregnant women or prisoners.

Study Design

Enrollment

70000 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

no intervention: Standard MatchMiner-AI Workflow

Oncologists can access the MatchMiner-AI frontend website to obtain a list of clinical trial options for all participants.

experimental: Proactive AI-Triggered Notifications

Oncologists receive email notifications containing a ranked list of potential clinical trial options when AI models detect progressive disease, in addition to standard MatchMiner-AI access.

Interventions

MatchMiner-AI Artificial Intelligence Tool

Oncologists receive email notifications containing a ranked list of potential clinical trial options when AI models detect progressive disease, in addition to standard MatchMiner-AI access.

Primary outcome measure

  • Proportion clinical trials [ Time Frame: Assessment will occur at the end of the 1.5 year duration of the intervention. ]

Central Contacts and Locations

Central contacts

Kenneth L Kehl, MD

617-632-4550kenneth_kehl@dfci.harvard.edu

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Kenneth Kehl, MD, MPH

617-632-4550Kenneth_Kehl@dfci.harvard.edu

Principal Investigator:

Kenneth Kehl, MD, MPH

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Sep 16, 2026

Last verified

Sep, 2026

Keywords

  • Cancer
  • Clinical Trial Enrollment
  • Electronic Health Records
  • Artificial Intelligence

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-18. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-09-16.